1238 Risk evaluation of immune checkpoint inhibitor diabetes through islet autoantibodies & HLA types in a large, real-world cohort

• Mark Anderson,
• Christine Spencer,
• Kevan Herold,
• Ashis Saha,
• Christian Hammer,
• Marshall Thompson,
• Samantha Liang,
• Zoe Quandt,
• Anastasia Lucas,
• Arabella Young

Affiliations

Mark Anderson

1University of California San Francisco, San Francisco, CA, USA

Christine Spencer

Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

Kevan Herold

Aff3 0000000419368710grid.47100.32Departments of ImmunbiologyYale School of Medicine 333 Cedar Street 06520 New Haven CT USA

Ashis Saha

1Genentech, South San Francisco, CA, United States

Christian Hammer

1Genentech, South San Francisco, CA, United States

Marshall Thompson

1Parker Institute for Cancer Immunotherapy (PICI), San Francisco, CA, USA

Samantha Liang

1Parker Institute for Cancer Immunotherapy, Castro Valley, CA, USA

Zoe Quandt

University of California San Francisco, San Francisco, CA, USA

Anastasia Lucas

3University of Pennsylvania, Philadelphia, PA, USA

Arabella Young

7Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA